|
FY2025
12 months to Dec 28, 2025
|
FY2024
12 months to Dec 29, 2024
|
FY2023
12 months to Dec 31, 2023
|
FY2022
12 months to Jan 1, 2023
|
FY2021
12 months to Jan 2, 2022
|
|
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Gross profit (loss) | |||||
| Operating expenses: | |||||
| Research and development | |||||
| Selling, general and administrative | |||||
| Impairment of equipment | |||||
| Restructuring cost | |||||
| Total operating expenses | |||||
| Loss from operations | |||||
| Other income (expense): | |||||
| Change in fair value of common stock warrants | |||||
| Gain on bargain purchase of assets | |||||
| Interest income | |||||
| Interest expense | |||||
| Other income (expense), net | |||||
| Total other income (expense), net | |||||
| Comprehensive Income (Loss), Net of Tax, Attributable to Parent | |||||
| Loss before income tax benefit | |||||
| Income tax benefit | |||||
| Net loss | |||||
| Net gain (loss) attributable to non-controlling interests | |||||
| Net loss attributable to Enovix | |||||
| Net loss per share attributable to Enovix shareholders, basic (in dollars per share) | |||||
| Weighted average number of common shares outstanding, basic (in shares) | |||||
| Net loss per share attributable to Enovix shareholders, diluted (in dollars per share) | |||||
| Weighted average number of common shares outstanding, diluted (in shares) | |||||
Loading...